How much weight can you lose each week on Wegovy?

What the STEP 1 trial actually measured week by week

The clearest picture of Wegovy's weight-loss trajectory comes from the STEP 1 trial, published in the New England Journal of Medicine. Over 68 weeks, adults with obesity or overweight who took semaglutide 2.4mg alongside lifestyle changes lost an average of around 14.9% of their starting body weight, compared with 2.4% in the placebo group. That works out to roughly 12–15 kg for many participants, depending on their starting weight.

The trajectory was front-loaded. Loss was steepest in roughly the first 16 to 20 weeks, then continued more gradually through to week 68. By the end of the dose escalation phase (when participants were still moving toward the 2.4mg maintenance dose) weekly losses were often more modest or intermittent. This is a pharmacological pattern, not a sign of failure: the body is adjusting to each new dose level before the next one begins.

Translated into weekly terms, the trial average sits somewhere between half a pound and two pounds a week across the full treatment period, and a detailed breakdown of average weekly weight loss on Wegovy shows how that figure shifts across different phases of treatment. Weeks at the lower end of that range are just as normal as the better ones. Anyone expecting a perfectly consistent weekly drop is likely to be frustrated, and possibly unnecessarily so. For a closer look at how results compare to tirzepatide and other options, the evidence on Wegovy's overall results sets the full picture.

Why the first few weeks look different from the rest

The first pen is 0.25mg, a dose chosen to let the body settle rather than produce rapid loss. Nausea and other gastrointestinal effects are most likely here, and they can affect appetite and fluid intake in ways that distort the scales in either direction. Some people see a notable early drop; others see almost nothing until the titration progresses. Both experiences sit well within the documented range.

The dose climbs through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, with at least four weeks at each level. Meaningful, sustained loss typically builds as the maintenance dose approaches. This is worth holding in mind if the first couple of pens feel underwhelming, what to expect in the first week on Wegovy explains what that initial phase usually looks like in practice.

One practical note: if your titration schedule happens to coincide with a holiday week or a particularly demanding stretch at work, a slower week on the scales can feel disproportionately discouraging. It rarely means anything clinically significant. The question to ask is whether the trend over four to eight weeks is moving in the right direction, not whether last Tuesday's weigh-in matched the previous one.

Anyone who has gone two or three weeks with no movement at all during the escalation phase may find the reasons behind a plateau in week two worth reading.

When weekly loss slows down, and what the evidence says about plateaus

Around the six-month mark on the maintenance dose, weight loss tends to decelerate for most people. This is not specific to Wegovy; it reflects how the body responds to sustained energy restriction of any kind. Metabolic adaptation, shifts in body composition and changes in hunger signalling all contribute. The NHS semaglutide medicines page notes that treatment should be reviewed if less than 5% of starting weight has been lost after six months at the maintenance dose, a threshold that also appears in NICE's recommendation for semaglutide (TA875).

A plateau at month eight or nine, after solid earlier progress, is qualitatively different from seeing no meaningful response at all. Most people in the STEP 1 trial who reached the 2.4mg dose did achieve clinically significant weight loss; the ones who did not were identifiable relatively early. If you have been on the maintenance dose for several months with little progress, that is a conversation to have with your prescriber, not something to manage alone by changing how you inject or when.

The higher 7.2mg dose, approved by the MHRA in January 2026 and available as a single-dose pen from April 2026, offers a further option for people who plateau at 2.4mg, though it is not appropriate for everyone and requires clinical assessment. If you are wondering how long Wegovy typically takes to produce noticeable results, this page on Wegovy's timeline covers the expected arc from first injection to plateau.

Getting clinical oversight that matches the pace of your progress

Weekly weight loss on Wegovy is a useful signal, but it is a poor substitute for proper clinical monitoring. The rate of loss matters less than the overall direction, the tolerability of treatment and whether any side effects are being managed appropriately. A prescriber who reviews your progress regularly is in a much better position to judge whether your current dose is right, whether your timeline is realistic and whether anything needs to change.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before dispatch, a real clinician reading your update, not an automated tick-box. Our team is available seven days a week for aftercare questions in between. If you have been reading about Wegovy and want to understand whether it might be suitable for you, our Wegovy treatment page covers eligibility and what the consultation involves. You can also explore our full range of weight-loss treatments if you would like to compare options before deciding. Speak to our prescribers through a free consultation, there is no obligation, and the clinical assessment is what ensures the medicine is right for your situation.